What Alizine Treats: Main Uses and Benefits

Alizine (Aglepristone) may be applied in managing progesterone-dependent clinical and reproductive states in female dogs and cats, which contributes to therapeutic management. The medication is considered relevant across several key reproductive and gynecological domains.

Quick Fact: Relief for Progesterone-Driven Symptoms

Alizine supports patients during difficult episodes by easing distress and physical burden associated with pathological uterine accumulation and unwanted pregnancy status. This provides supportive relief when symptoms interfere with routine activities, helping to improve day-to-day comfort during symptomatic phases.

---

The medication is commonly used to help with managing the status of unwanted gestation in situations involving unwanted gestation, and assists with functional stability when managing acute episodes of progesterone-dependent pathology, such as Pyometra (uterine infection). Additionally, in female cats (queens), Alizine is applied to address symptom clusters that may become intense or disruptive, such as the rapid enlargement of mammary tissue in feline fibroadenomatosis.

---

Supportive Management of Uterine Conditions

This medication is commonly used across conditions presenting with acute episodes of progesterone-dependent pathology. This use assists with functional stability by potentially supporting uterine drainage and supporting the return to a stable state, which may help patients cope more steadily with symptom fluctuations related to severe disease.

---

Supportive Management of Progesterone-Driven Tissue Overgrowth

Alizine is relevant in contexts marked by increased discomfort or tension and is generally used to help with easing the symptoms related to the physical overgrowth, which supports patients during difficult episodes by easing distress and physical burden.

Regulatory References

1. Veterinary Medicines Directorate Summary of Product Characteristics

The eligibility for Alizine (Aglepristone) is strictly defined by regulatory authorities based on the target species and the presence of specific pre-existing health conditions. The medicine is officially licensed for use only in dogs (bitches) for the induction of abortion, and only up to 45 days after mating.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Dogs (bitches) for the licensed purpose of inducing abortion up to day 45 of gestation.
Populations for whom use is contraindicated	Dogs with impaired hepatic or renal function, diabetic animals, or those in poor health.
Comorbidity-based exclusions	Dogs with manifest or latent hypoadrenocorticism (Addison’s disease) or a genetic predisposition to the condition.
Condition-specific eligibility rules	Use must be with caution in dogs with cardiovascular disease (especially bacterial endocarditis) or chronic obstructive-airway disease.
Pregnancy and lactation eligibility status	Pregnancy is a contraindication unless the goal is termination; safety is not established during lactation.

Connection to the overall eligibility profile

The regulatory documents establish absolute non-eligibility (contraindication) for any dog presenting with certain pre-existing conditions, including severe liver or kidney impairment, diabetes, and endocrine disorders like hypoadrenocorticism. The official rules permit use only in reproductive-age bitches free from these specific health risks and only within the initial 45 days of pregnancy.

Alizine (Aglepristone) possesses a structured interaction profile established by regulatory authorities, encompassing pharmacodynamic antagonism, potential pharmacokinetic interference, and a major procedural incompatibility. All interaction information is based strictly on the Summary of Product Characteristics (SmPC).

Interacting Substance/Class	Official Interaction Classification	Resulting Regulatory Constraint
Glucocorticoids (Corticosteroids)	Pharmacodynamic Antagonism	Aglepristone may reduce the intended effect of glucocorticoid treatment.
Progestins (Synthetic or Natural)	Pharmacodynamic Antagonism	Co-administration could reduce the efficacy of Aglepristone.
Ketoconazole, Itraconazole, Erythromycin	Potential Pharmacokinetic Risk	Formal statement that a risk of drug interaction may exist.

Mandatory Procedural Constraint

The Alizine solution must not be mixed with any other veterinary medicinal product due to a labeled physical and chemical incompatibility. This constraint is an official requirement for the preparation and administration of the product. The overall interaction map is defined by these specific restrictions and the officially recognized antagonism against both glucocorticoid and progestin compounds, ensuring the profile is strictly aligned with government regulatory documents.

How Alizine Works: Mechanism of Action

Alizine's active ingredient, Aglepristone, functions as a steroidal anti-progestin, engaging a cascade that interrupts the physiological process maintained by Progesterone. The core action is a highly specific receptor blockade that leads to systemic functional changes via the mechanism's kinetics.

Competitive Blockade of the Progesterone Receptor

The primary mechanism involves Aglepristone binding competitively and with high affinity to the Progesterone Receptor ( PR). This action constitutes a direct anti-hormonal blockade at the molecular level, preventing the natural hormone, Progesterone, from accessing and activating the PR in target tissues like the uterus. This interaction is the initiating event for the downstream physiological sequence by interrupting the Progesterone-mediated influence on the tissue.

Functional Modulation of Uterine and Systemic Physiology

The resulting lack of PR signaling in the uterus removes the hormone's Progesterone-mediated inhibition of contractility, initiating a reversal of the uterine quiescence state. This functional modulation concurrently triggers local release of signaling molecules that facilitate luteolysis (regression of the Corpus Luteum), which is a source of Progesterone. The combined effect results in increased myometrial contractility and cervical softening.

How to Use Alizine

Alizine (Aglepristone) is administered according to a specific, standardized protocol to ensure its proper use. This section outlines the protocol for administration and dosing.

---

Standard Administration Protocol

Feature	Instruction
Route of Administration	Strictly by subcutaneous injection only.
Dosing Schedule	10 mg of Aglepristone per kg of bodyweight (0.33 mL of 30 mg/mL solution per kg).
Frequency	Two separate injections are required.
Timing	The second injection must be given 24 hours after the first.
Injection Site	Administered into the scruff of the neck.

---

Procedural Conditions and Timeframe

The treatment may be administered up to 45 days following mating. If the calculated dose volume exceeds 5 mL, the total quantity must be divided and administered into separate subcutaneous injection sites. Following each administration, a light massage of the injection site is recommended as part of the standard procedure. A repeat treatment following the same regimen may be considered 10 days after the initial course if necessary, provided the patient remains within the designated timeframe.

This structured, two-part injection course defines a precise, time-critical administration protocol based on the patient's bodyweight and specific constraints on injection volume.

Research evidence / Overview of studies for Alizine

---

Evidence for Use in Managing Unwanted Gestation

Research into Alizine's use for unwanted gestation was evaluated in dogs (bitches) and cats (queens) across various stages of early and mid-pregnancy. The evidence base primarily includes Randomized Controlled Trials (RCTs) and multicenter field trials, which are authoritative study designs. These studies explored the overall success rate of interrupting the pregnancy and research examined the time frame required for the process to be complete.

For bitches in the early to mid-gestation phase, findings describe patterns observed in the studies that assessed the rate of pregnancy interruption. The research indicates the time needed for the process to occur, noting that this period may vary between individual animals. Long-term studies monitored the animals to understand their subsequent fertility and the timing of their next reproductive cycle.

Research on Medical Management of Pyometra

Research exploring Alizine's use for the medical management of pyometra, an acute uterine infection, is largely derived from Observational Case Series and Comparative Studies. Research describes the evaluation of this medication in bitches and queens presenting with this condition associated with acute or disruptive episodes.

The studies explored outcomes related to the overall clinical condition, such as the rate of clinical recuperation (resolution of systemic signs like fever or lethargy) and how the uterus changed (measured as uterine involution via ultrasound). In many instances, Alizine was observed in some studies to be administered as part of a combination regimen alongside other treatments, such as antibiotics.

---

What Research Gaps and Uncertainties Remain

The certainty remains low for certain uses, such as in late-stage gestation termination and in the management of severe, septic pyometra, as data for these cases remain insufficient within the available research landscape. Furthermore, many studies, particularly those on pyometra, used Alizine as part of a combination treatment, meaning the individual contribution of the drug may be uncertain. Data for long-term outcomes and for feline populations remain insufficient compared to the core evidence available for dogs.

Key Studies & References

1. SUMMARY OF PRODUCT CHARACTERISTICS (SPC) for Alizin 30 mg/ml Solution for Injection for dogs (Regulatory document covering indications, contraindications, and study summary)

Common questions about Alizine (FAQ)

---

Q: How quickly should I expect Alizine to start working?

According to official product information, the process of abortion or resorption following the two required injections is generally observed to occur within 7 days of the treatment course.

Q: Does Alizine have a sedative effect that causes drowsiness?

Regulatory documents list systemic adverse reactions such as depression and excitation as 'Very Common.' Drowsiness or general sedation are not specifically listed among the most frequently reported side effects in the official product information.

Q: Can Alizine affect my sleep cycle?

The official product information lists systemic adverse reactions such as depression and excitation. These effects may affect normal rest patterns, but a direct impact on the 'sleep cycle' is not detailed in the regulatory safety summary.

Q: How long does Alizine typically stay in your system?

Pharmacokinetic data from regulatory sources indicate that the active ingredient, Aglepristone, achieves its highest concentration around 2.5 days after the injections. The overall mean residence time (the average time it stays active in the system) is approximately 6 days.

Q: Is Alizine safe to take with common pain relievers like ibuprofen?

The product label limits its interaction warnings to a few specific classes (Glucocorticoids, Progestins, etc.) and states that interactions with most other drugs, including non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, have not been formally studied.

Q: Can I take Alizine with my regular vitamins or herbal supplements?

The interaction section is limited to prescription drugs, and official information states that interactions with other substances, including supplements, have not been formally studied. Users should rely on their veterinarian for advice on concurrent use.

Q: Why do some people experience headaches when taking Alizine?

Headaches are not listed in the official adverse reaction tables (Very Common or Common) provided in the regulatory documents for Alizine.

Q: Can Alizine interact with blood pressure medication?

The product label limits its interaction warnings to a few specific classes and states that interactions with most other drugs, including blood pressure medication, have not been formally studied.

Q: Do older adults need to adjust anything when taking Alizine?

The regulatory documents do not provide age-specific dosing adjustments. However, the use of Alizine is strictly contraindicated in patients with pre-existing conditions like impaired kidney or liver function and diabetes, which may be more prevalent in older animals.

Q: Are there any known interactions between Alizine and alcohol?

The product itself is formulated using an oil and alcohol base. Official documents do not contain specific warnings about interactions with orally consumed alcohol.

Q: How often is Alizine usually taken?

The standard administration protocol is highly specific, requiring two consecutive injections administered exactly 24 hours apart.

Q: Will Alizine interfere with the effectiveness of birth control pills?

Aglepristone works as an anti-progestin, blocking the effects of the hormone Progesterone. Regulatory documents warn of a risk of reduced efficacy if Alizine is given concurrently with other Progestins (such as those used in some hormonal contraceptives).

Q: Is Alizine approved for use in children?

Alizine is a veterinary medicinal product and is not approved for use in humans (including children). Its use is restricted to dogs (bitches) for a specific indication.

Q: What should I do if the side effects from Alizine feel too strong?

Official product information notes that the patient should be re-examined by a veterinarian if the signs after treatment are unexpected or persist longer than anticipated.

Q: Can Alizine be taken on an empty stomach?

Alizine is administered strictly by subcutaneous injection (under the skin), not orally. Therefore, the state of the stomach (empty or full) is not a relevant procedural factor for its administration.

Q: Are there any studies comparing Alizine to non-pharmacological treatments?

The research overviews summarized in the regulatory documents focus primarily on efficacy and safety trials, typically comparing the drug against a placebo or other pharmaceutical regimens. Direct comparisons with non-pharmacological methods are not a standard feature of the regulatory summary.

Q: Does taking Alizine cause weight gain or loss?

Weight changes are not explicitly listed as a Very Common or Common adverse reaction in the official product safety information. However, anorexia (lack of appetite) is reported as a Very Common side effect.

Q: Can I drive or operate heavy machinery while taking Alizine?

Alizine is a veterinary product. The official label contains warnings for human handlers to avoid accidental self-injection, particularly for pregnant women, but it does not contain advice on driving.

Q: Does Alizine interact with common acid reflux medications?

The regulatory document's interaction section is limited to specific drug classes and states that interactions with other medications, including those for acid reflux, have not been formally studied.

Q: Is Alizine an immunosuppressant drug?

Alizine is officially classified as a steroidal anti-progestin that acts by blocking the progesterone receptor. While it has anti-glucocorticoid properties, it is not classified as an immunosuppressant.

Q: Can Alizine be used by people with a history of heart issues?

Alizine is a veterinary product and is not for human use. The official documents state that caution is advised for its use in dogs with pre-existing cardiovascular disease, especially bacterial endocarditis.

Q: What makes Alizine different from a steroid medication?

Aglepristone, the active ingredient in Alizine, is a synthetic steroid compound. It is specifically classified as a steroidal anti-progestin because it works by blocking the effects of the natural steroid hormone, Progesterone.

Q: Are there any rare but serious side effects associated with Alizine?

The regulatory documents warn that the serious risk associated with lack of efficacy (abortion failure) includes the possibility of complications like dystocia or uterine rupture, which can, in very rare instances, lead to a fatal outcome. Hypersensitivity reactions are also reported as a rare event.

Q: Has the FDA (or similar agency) given any special warnings about Alizine?

Official regulatory documents, such as the European Summary of Product Characteristics, carry special warnings for the handler. These state that accidental self-injection or skin contact should be avoided, especially by women who are pregnant or whose pregnancy status is unknown.

Q: Are there any common lab tests that Alizine might interfere with?

Yes, official data from field trials indicate that the administration of Alizine may induce transient and reversible modified haematological (blood) and biochemical values in some patients.

Q: Can Alizine cause stomach issues or digestive upset?

Yes, according to the official safety profile, diarrhoea is listed as a Very Common side effect (affecting more than 1 in 10 patients), and vomiting is listed as a Common side effect (affecting 1 to 10 in 100 patients).

Q: Is it normal to feel slightly dizzy after starting Alizine?

Dizziness is not specifically listed as a Very Common or Common adverse reaction in the regulatory documents. The most common systemic effects reported are depression and excitation.

Q: What are the signs of a serious allergic reaction to Alizine?

Official regulatory documents report that hypersensitivity reactions (allergic reactions) occur in rare cases. Specific signs or symptoms of a serious allergic reaction are not detailed in the general adverse reaction tables, only the frequency.

Q: What is the typical duration of treatment with Alizine?

The treatment protocol requires two injections 24 hours apart. Official instructions state that a repeat treatment may be considered if needed, 10 days after the initial course.

How to Store and Dispose of Alizine

Official regulatory documents specify mandatory conditions to ensure the stability and safe handling of the Alizine injectable solution.

Storage Requirements

The product must be stored at a temperature below 25°C and protected from light by remaining in its original container and outer carton. The unopened product has a shelf-life of 3 years. Once the vial is broached (opened), the contents are only stable and usable for 28 days, after which the remaining portion must be discarded. As a mandatory safety precaution, Alizine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Alizine must not be disposed of in household waste or wastewater. Due to its documented environmental risk, disposal must strictly follow local pharmaceutical waste regulations and official collection schemes, such as returning the product to the veterinary surgeon or an authorized disposal service.